The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10917 malaria professionals are enjoying the free benefits of MalariaWorld today

artemether-lumefantrine

Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in four malaria endemic states of India

May 26, 2021 - 09:19 -- Open Access
Author(s): 
Sri Krishna, Sweta Mishra, Praveen K. Bharti, et al.
Reference: 
Malaria Journal 2021 20:229, 21 May 2021

Malaria is a major public health problem in India and accounts for about 88% of malaria burden in South-East Asia. India alone accounted for 2% of total malaria cases globally. Anti-malarial drug resistance is one of the major problems for malaria control and elimination programme. Artemether-lumefantrine (AL) is the first-line treatment of uncomplicated Plasmodium falciparum in north eastern states of India since 2013 after confirming the resistance against sulfadoxine-pyrimethamine. In the present study, therapeutic efficacy of artemether-lumefantrine and k13 polymorphism was assessed in uncomplicated P. falciparum malaria.

NOT Open Access | Evaluation of the effects of atazanavir-ritonavir on the pharmacokinetics of lumefantrine in patients living with HIV in Lagos University Teaching Hospital, South-Western Nigeria

March 24, 2021 - 15:10 -- NOT Open Access
Author(s): 
Usman SO, Oreagba IA, Akanmu AS, et al.
Reference: 
Eur J Clin Pharmacol. 2021 Mar 23

Atazanavir-ritonavir (ATVr)-based antiretroviral therapy and artemether-lumefantrine (AL) are commonly used drugs for the treatment of human immune deficiency virus (HIV) infection and malaria respectively. However, interaction of both drugs, with Cytochrome P 3A4 (CYP 3A4) isoenzyme, may spawn clinically significant pharmacokinetic interactions. This study evaluated the effects of atazanavir-ritonavir on the pharmacokinetics of lumefantrine.

Monitoring of the Sensitivity In Vivo of Plasmodium falciparum to Artemether-Lumefantrine in Mali

January 31, 2021 - 15:43 -- Open Access
Author(s): 
Diarra M, Coulibaly D, Sagara I, et al.
Reference: 
Trop Med Infect Dis. 2021 Jan 24;6(1):13

In Mali, since 2007, artemether-lumefantrine has been the first choice against uncomplicated malaria. Despite its effectiveness, a rapid selection of markers of resistance to partner drugs has been documented. This work evaluated the treatment according to the World Health Organization's standard 28-day treatment method.

Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017–2018

January 20, 2021 - 08:38 -- Open Access
Author(s): 
Adama Gansané, Leah F. Moriarty, Halidou Tinto, et al.
Reference: 
Malaria Journal 2021 20:48, 19 January 2021

The World Health Organization recommends regularly assessing the efficacy of artemisinin-based combination therapy (ACT), which is a critical tool in the fight against malaria. This study evaluated the efficacy of two artemisinin-based combinations recommended to treat uncomplicated Plasmodium falciparum malaria in Burkina Faso in three sites: Niangoloko, Nanoro, and Gourcy.

Plasmodium falciparum multidrug resistance gene-1 polymorphisms in Northern Nigeria: implications for the continued use of artemether-lumefantrine in the region

December 2, 2020 - 07:48 -- Open Access
Author(s): 
Auwal Adamu, Mahmoud Suleiman Jada, Mohammed Nasir Shuaibu, et al.
Reference: 
Malaria Journal 2020 19:439, 30 November 2020

The analysis of single nucleotide polymorphism (SNPs) in drug-resistance associated genes is a commonly used strategy for the surveillance of anti-malarial drug resistance in populations of parasites. The present study was designed and performed to provide genetic epidemiological data of the prevalence of N86Y-Y184F-D1246Y SNPs in Plasmodium falciparum multidrug resistance 1 (pfmdr1) in the malaria hotspot of Northern Nigeria.

Trends in health workers’ compliance with outpatient malaria case-management guidelines across malaria epidemiological zones in Kenya, 2010–2016

November 12, 2020 - 15:55 -- Open Access
Author(s): 
Beatrice Amboko, Kasia Stepniewska, Peter M. Macharia, Beatrice Machini, Philip Bejon, Robert W. Snow and Dejan Zurovac
Reference: 
Malaria Journal 2020 19:406, 11 November 2020

Health workers' compliance with outpatient malaria case-management guidelines has been improving, specifically regarding the universal testing of suspected cases and the use of artemisinin-based combination therapy (ACT) only for positive results (i.e., ‘test and treat’). Whether the improvements in compliance with ‘test and treat’ guidelines are consistent across different malaria endemicity areas has not been examined.

Prevalence and factors associated with carriage of Pfmdr1 polymorphisms among pregnant women receiving intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) and artemether-lumefantrine for malaria treatment in Burkina Faso

November 11, 2020 - 14:20 -- Open Access
Author(s): 
Hamtandi Magloire Natama, Rouamba Toussaint, Djamina Line Cerine Bazié, Sékou Samadoulougou, Maminata Coulibaly-Traoré, Halidou Tinto and Fati Kirakoya-Samadoulougou
Reference: 
Malaria Journal 2020 19:399, 10 November 2020

Single nucleotide polymorphisms occurring in the Plasmodium falciparum multidrug resistant gene 1 (pfmdr1) are known to be associated with aminoquinoline resistance and, therefore, represent key P. falciparum markers for monitoring resistance both in susceptible groups (children under 5 years old and pregnant women) and in the general population. This study aimed to determine prevalence and factors associated with the carriage of pfmdr1 N86Y, Y184F and D1246Y polymorphisms among pregnant women in a setting of high malaria transmission in Burkina Faso.

Continued low efficacy of artemether-lumefantrine in Angola, 2019

November 11, 2020 - 12:56 -- Open Access
Author(s): 
Dimbu PR, Horth R, Pluciński MM, et al.
Reference: 
Antimicrob Agents Chemother. 2020 Nov 9:AAC.01949-20.

Biennial therapeutic efficacy monitoring is a crucial activity for ensuring efficacy of currently used artemisinin-based combination therapy in Angola.

Not Open Access | Teratogen update: Malaria in pregnancy and the use of antimalarial drugs in the first trimester

October 21, 2020 - 09:39 -- NOT Open Access
Author(s): 
Clark RL
Reference: 
Birth Defects Res. 2020 Oct 20

Malaria is a particular problem in pregnancy because of enhanced sensitivity, the possibility of placental malaria, and adverse effects on pregnancy outcome. Artemisinin-containing combination therapies (ACTs) are the most effective antimalarials known. WHO recommends 7-day quinine therapy for uncomplicated Plasmodium falciparum malaria in the first trimester despite the superior tolerability and efficacy of 3-day ACT regimens because artemisinins caused embryolethality and/or cardiovascular malformations at relatively low doses in rats, rabbits, and monkeys.

Pages

Subscribe to RSS - artemether-lumefantrine